A clinical stage biopharmaceutical company focused on developing therapeutics for autoimmune-driven inflammatory diseases
About Us
Eliem Therapeutics, following the close of the acquisition of Tenet Medicines, will be focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy.
Our Pipeline
TNT119, an anti-CD19 mAb, is designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. This reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as SLE, ITP and MN. In a Phase 1b clinical trial of TNT119 in MN, 3 out of 5 (or 60%) of patients that received four doses of TNT119 achieved a complete remission of proteinuria, a primary symptom of MN.
In SLE, one of TNT119’s lead indications, the underlying pathology involves production of autoantibodies by autoreactive B cells that contribute to inflammation and tissue damage. Because TNT119 is designed to target and deplete CD19-expressing B cells known to produce autoantibodies, the Company believes TNT119 has the potential to treat SLE.
In ITP, the Company believes targeting plasmablasts and plasma cells is likely to decrease the production of autoantibodies, increase platelet count and ameliorate disease. B cell depletion with anti-CD20 targeting mAbs, has demonstrated efficacy in some patients with ITP based on in clinical trials conducted by third parties. For those patients who do not respond to anti-CD20 therapy, the Company believes an anti-CD19 approach, such as TNT119, may have the ability to further deplete pathogenic CD20-/CD19+ cells.
Our Experienced Team
Aoife brings to Eliem over 20 years of experience leading drug development organizations across a range of stages and therapeutic areas having most recently served as the President and Chief Executive Officer of Synlogic, a clinical stage biotechnology company developing treatments for rare metabolic diseases based on synthetic biology. In that role, she led the organization from early-stage private company to a late-phase public company with internal GMP manufacturing capabilities, pioneering new regulatory pathways for bacterial therapeutics. She joined Synlogic as Chief Medical Officer in 2016 and was promoted to CEO in October 2018. Prior to Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen, Inc., where she led the global marketing approvals of ALPROLIX®, ELOCTATE® and SPINRAZA® as well as other early-stage programs. She served as a director of Synlogic from October 2018 to March 2024, as a director of Ra Pharmaceuticals, Inc. from Sept 2018 through its acquisition in April 2020 and currently serves as a director of Fibrogen Inc., Cerevance, LLC and Xilio Therapeutics. Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and completed her post-graduate training in internal medicine, endocrinology and metabolism at the Royal College of Physicians in Ireland. She also completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Jan is a rheumatologist and clinical immunologist with 20 years of experience in academic research, patient care and teaching, and more than 15 years of experience in the biotech industry spanning translational, preclinical, early and late clinical development. Prior to Eliem, Dr. Hillson was a Partner at Cascadia Drug Development Group providing strategic advisory support, including indication prioritization, investment opportunity diligence, and planning and oversight of therapeutic development with a focus in immunology. Dr. Hillson’s experience in the biotechnology industry includes senior clinical development and leadership roles at ZymoGenetics (acquired by Bristol Myers Squibb), Momenta (acquired by Johnson & Johnson), Chemocentryx (acquired by Amgen), Alpine Immune Sciences, and Provention Bio (acquired by Sanofi), where she was responsible for the design and execution of clinical development plans and trials for multiple therapeutic candidates in autoimmune diseases and immunovirology. Dr. Hillson is currently serving on the Board of Directors for Eledon Pharmaceuticals. Dr. Hillson received her M.D. from Stanford School of Medicine, an M.S. from the California Institute of Technology, an M.S. in Marine Chemistry from Scripps Institute of Oceanography, and a B.S. from Michigan State University.
News
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
By Bob Azelby
More restrictive opioid prescribing guidelines were put in place in a rightful effort to stop a devastating crisis. But this sudden and dramatic change negatively impacted chronic pain patients who were managing their pain through prescription opioids given few other effective options.
Careers
We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.
We’d love to connect.
Department: Finance
Hiring Manager: Controller
Effective Date: Immediate
Location: Remote, Greater Seattle Area, Washington
About Eliem:
Eliem is a dynamic, rapidly growing public company that is set to make significant strides in the life sciences industry. In April 2024, Eliem announced an agreement to acquire Tenet Medicines, Inc. and a concurrent $120 million private placement of common stock with a syndicate of new and existing institutional life science investors. The combined company plans to focus on advancing TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy.
The acquisition and the private placement are expected to close in the middle of 2024, subject to Eliem stockholder approval and other customary closing conditions.
The company has teams located in both the US and UK. For further information visit our website: https://eliemtx.com.
About this role:
Are you ready for a change from public accounting and eager to apply your financial reporting and technical accounting expertise in an industry setting? Do you want to join a company that’s at the forefront of a dynamic industry, aiming to help patients lead happier, more fulfilling lives? If so, we invite you to join our growing accounting team as an SEC Reporting Senior Associate or Manager. In this crucial role, you will report to the Controller and collaborate with key internal and external stakeholders to ensure timely and accurate internal and external reporting in accordance with GAAP.
Responsibilities
- Manage all aspects of our external SEC documents, including the 10K, 10Q, 8K and other ad hoc filings
- Play a key role in implementation efforts and continuous monitoring of significant new accounting and SEC pronouncements including communicating and educating financial management on the updates
- Lead efforts on technical accounting matters, including research and drafting of memos and policies
- Complete disclosure checklists to ensure all requirements are met; stay updated on new pronouncements impacting disclosures; and maintain a repository of internal practices and peer company disclosures
- Manage the preparation and support for all areas of our external reporting process, including EPS calculations, Balance Sheet, Income Statement, Statement of Cash Flows, Statement of Stockholders’ Equity, and Share-Based Compensation
- Coordinate the review of filings with external auditors, legal counsel, accounting staff and executive management
- Play a key role in the external audit process
- Complete, document and communicate/present ad-hoc projects and analyses
- Assist with the review of our annual tax provision and returns
- Support Sarbanes-Oxley (SOX) compliance efforts, including the execution of financial reporting and equity processes controls.
Experience
- Bachelor’s degree in Accounting/Finance and CPA required
- Strong understanding of US GAAP and SEC reporting rules and regulations
- Excellent organizational, verbal, and written communication skills
- Proficiency in accounting research and problem-solving
- 4+ years of experience in accounting; including Big 4 public accounting experience with exposure to public company reporting
- Strong project management skills and the ability to manage a process, multi-task, work under pressure, and meet deadlines in a fast-paced work environment
- Ability to build and maintain strong relationships with internal and external business partners
- Ability to operate independently and as part of a larger functional team
- Proficiency with Microsoft Office – Word, Excel, and PowerPoint
If you are passionate about leveraging your accounting skills in a thriving company and making a real impact in the life sciences industry, we encourage you to apply and become part of the Eliem team.
The physical demands described here are representative of those that must be met by an employee to successfully perform the primary functions of this job. This role is performed primarily from home with occasional site visits, the conditions of which may vary.
- Work is normally performed in a home or professional indoor office work environment
- Continuously remain in a sedentary position the majority of the day – employees are expected to create and maintain an ergonomic workstation
- Operate a computer with time spent looking at monitor about 85% of the time
- Communicate and exchange accurate information clearly with others
- Continuously able to interpret visual content displayed on a digital screen
- Very limited to no exposure to physical risk
- Very limited to no physical effort required
- Walk or stand occasionally
- Use hands, wrists, and fingers to manipulate, control, or feel objects, tools, or equipment
- Move about inside the office to access file cabinets, office machinery, etc.
- Must be able to lift, move, push, pull, or otherwise manipulate objects of at least 10 pounds
The base pay range for this position at commencement of employment is expected to be $115,000-135,000. Base salary offered may vary depending on individual’s skills, experience, and competitive market value. Additional total rewards include discretionary annual bonus, comprehensive benefits to include Medical, Dental and Vision, short-term and long-term disability, company paid basic life insurance, 401k company match, generous paid time off and paid holiday, and stock options. Qualified candidates are encouraged to forward their resumes to CareersUS@eliemtx.com.
Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.
Department: Finance
Hiring Manager: Controller
Effective Date: Immediate
Location: Remote, Greater Seattle Area, Washington
About Eliem:
Eliem is a dynamic, rapidly growing public company that is set to make significant strides in the life sciences industry. In April 2024, Eliem announced an agreement to acquire Tenet Medicines, Inc. and a concurrent $120 million private placement of common stock with a syndicate of new and existing institutional life science investors. The combined company plans to focus on advancing TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy.
The acquisition and the private placement are expected to close in the middle of 2024, subject to Eliem stockholder approval and other customary closing conditions.
The company has teams located in both the US and UK. For further information visit our website: https://eliemtx.com.
About this role:
Are you ready for a change from public accounting and eager to apply your financial reporting and technical accounting expertise in an industry setting? Do you want to join a company that’s at the forefront of a dynamic industry, aiming to help patients lead happier, more fulfilling lives? If so, we invite you to join our growing accounting team as an SEC Reporting Senior Associate or Manager. In this crucial role, you will report to the Controller and collaborate with key internal and external stakeholders to ensure timely and accurate internal and external reporting in accordance with GAAP.
Responsibilities
- Manage all aspects of our external SEC documents, including the 10K, 10Q, 8K and other ad hoc filings
- Play a key role in implementation efforts and continuous monitoring of significant new accounting and SEC pronouncements including communicating and educating financial management on the updates
- Lead efforts on technical accounting matters, including research and drafting of memos and policies
- Complete disclosure checklists to ensure all requirements are met; stay updated on new pronouncements impacting disclosures; and maintain a repository of internal practices and peer company disclosures
- Manage the preparation and support for all areas of our external reporting process, including EPS calculations, Balance Sheet, Income Statement, Statement of Cash Flows, Statement of Stockholders’ Equity, and Share-Based Compensation
- Coordinate the review of filings with external auditors, legal counsel, accounting staff and executive management
- Play a key role in the external audit process
- Complete, document and communicate/present ad-hoc projects and analyses
- Assist with the review of our annual tax provision and returns
- Support Sarbanes-Oxley (SOX) compliance efforts, including the execution of financial reporting and equity processes controls.
Experience
- Bachelor’s degree in Accounting/Finance and CPA required
- Strong understanding of US GAAP and SEC reporting rules and regulations
- Excellent organizational, verbal, and written communication skills
- Proficiency in accounting research and problem-solving
- 4+ years of experience in accounting; including Big 4 public accounting experience with exposure to public company reporting
- Strong project management skills and the ability to manage a process, multi-task, work under pressure, and meet deadlines in a fast-paced work environment
- Ability to build and maintain strong relationships with internal and external business partners
- Ability to operate independently and as part of a larger functional team
- Proficiency with Microsoft Office – Word, Excel, and PowerPoint
If you are passionate about leveraging your accounting skills in a thriving company and making a real impact in the life sciences industry, we encourage you to apply and become part of the Eliem team.
The physical demands described here are representative of those that must be met by an employee to successfully perform the primary functions of this job. This role is performed primarily from home with occasional site visits, the conditions of which may vary.
- Work is normally performed in a home or professional indoor office work environment
- Continuously remain in a sedentary position the majority of the day – employees are expected to create and maintain an ergonomic workstation
- Operate a computer with time spent looking at monitor about 85% of the time
- Communicate and exchange accurate information clearly with others
- Continuously able to interpret visual content displayed on a digital screen
- Very limited to no exposure to physical risk
- Very limited to no physical effort required
- Walk or stand occasionally
- Use hands, wrists, and fingers to manipulate, control, or feel objects, tools, or equipment
- Move about inside the office to access file cabinets, office machinery, etc.
- Must be able to lift, move, push, pull, or otherwise manipulate objects of at least 10 pounds
The base pay range for this position at commencement of employment is expected to be $115,000-135,000. Base salary offered may vary depending on individual’s skills, experience, and competitive market value. Additional total rewards include discretionary annual bonus, comprehensive benefits to include Medical, Dental and Vision, short-term and long-term disability, company paid basic life insurance, 401k company match, generous paid time off and paid holiday, and stock options. Qualified candidates are encouraged to forward their resumes to CareersUS@eliemtx.com.
Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.
Contact Us
PMB #117
2801 Centerville Road, 1st Floor
Wilmington, DE 19808-1609
Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT